For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Tafinlar + Mekinist: The first targeted therapy indicated to treat BRAF V600+ NSCLC1

Combination Tafinlar + Mekinist: Efficacy results in first-line, treatment-naïve patients and second-line, previously treated patients with BRAF V600+ NSCLC (investigator and IRC assessed)

Efficacy Efficacy results in previously treated patients.

DoR, duration of response; IRC, independent review committee; NA, not available; NE, not evaluable; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.


References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial [published online September 8, 2017]. Lancet Oncol. doi:10.1016/S1470-2045(17)30679-4.